Skip to main content
  • Saved

made a Post

Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis - PubMed

Efficacy and safety of CDK4/6 and PI3K/AKT/mTOR inhibitors as second-line treatment in postmenopausal patients with hormone receptor-positive, HER-2-negative metastatic breast cancer: a network meta-analysis - PubMed

Source :

https://pubmed.ncbi.nlm.nih.gov/34047239/

doi: 10.1080/14740338.2021.1931116. Online ahead of print. 1 Department of Obstetrics and Gynecology, Chiayi Christian Hospital, Chiayi, Taiwan. 2 Department of Radiation Oncology, An Nan Hospital, China Medical University, Tainan, Taiwan. 3 Department of Radiology, An-Nan Hospital, China Medical University, Tainan, Taiwan. 4 Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.